Atossa Therapeutics, Inc. (ATOS)
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
ATOS Insider Trading Activity
ATOS Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $44,250 | 1 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Finn Jonathan | director | 1 | $44,250 | 0 | $0 | $44,250 |
About Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with …
Insider Activity of Atossa Therapeutics, Inc.
Over the last 12 months, insiders at Atossa Therapeutics, Inc. have bought $44,250 and sold $0 worth of Atossa Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Atossa Therapeutics, Inc. have bought $46,375 and sold $316,167 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Finn Jonathan (director) — $44,250.
The last purchase of 25,000 shares for transaction amount of $44,250 was made by Finn Jonathan (director) on 2024‑04‑10.
List of Insider Buy and Sell Transactions, Atossa Therapeutics, Inc.
| 2024-04-10 | Finn Jonathan | director | 25,000 0.0202% | $1.77 | $44,250 | -25.71% | ||
| 2023-11-15 | Sale | WEAVER GREGORY L | Former EVP, CFO, & Director | 50,000 0.0395% | $0.65 | $32,500 | +103.08% | |
| 2023-06-20 | WEAVER GREGORY L | EVP & CFO | 50,000 0.0401% | $0.97 | $48,500 | -1.19% | ||
| 2021-07-02 | Sale | WEAVER GREGORY L | director | 107,497 0.0883% | $5.58 | $599,833 | -69.09% | |
| 2017-11-15 | Guse Kyle | CFO, Gen Counsel and Secretary | 10,000 0.0857% | $0.34 | $3,369 | -23.53% | ||
| 2017-04-17 | Remmel H. Lawrence | director | 2,500 0.0345% | $0.63 | $1,580 | -24.59% | ||
| 2016-04-01 | Remmel H. Lawrence | director | 1,500 0.0044% | $0.33 | $495 | -57.08% | ||
| 2016-03-09 | QUAY STEVEN C | President & CEO | 15,000 0.0476% | $0.37 | $5,550 | -59.37% | ||
| 2016-03-09 | Chen Shu-Chih | 15,000 0.0476% | $0.37 | $5,550 | -59.37% | |||
| 2016-02-16 | QUAY STEVEN C | President & CEO | 15,000 0.0459% | $0.53 | $7,950 | -54.55% | ||
| 2016-02-16 | Chen Shu-Chih | 15,000 0.0459% | $0.53 | $7,950 | -54.55% | |||
| 2016-01-19 | QUAY STEVEN C | President & CEO | 50,000 0.1586% | $0.20 | $10,000 | +30.00% | ||
| 2016-01-19 | Chen Shu-Chih | 50,000 0.1586% | $0.20 | $10,000 | +30.00% | |||
| 2015-06-12 | Remmel H. Lawrence | director | 5,400 0.02% | $1.30 | $7,020 | -62.99% | ||
| 2013-11-21 | WEAVER GREGORY L | director | 20,000 0.1359% | $2.58 | $51,570 | -30.41% | ||
| 2013-10-01 | Sale | QUAY STEVEN C | CEO | 14,530 0.0922% | $5.66 | $82,211 | -67.88% | |
| 2013-10-01 | Sale | Chen Shu-Chih | Chief Scientific Officer | 14,530 0.0922% | $5.66 | $82,211 | -67.88% | |
| 2013-05-15 | CROSS ALEXANDER D | director | 1,000 0.0068% | $5.49 | $5,490 | -55.87% | ||
| 2013-01-08 | Remmel H. Lawrence | director | 6,000 0.0447% | $4.14 | $24,820 | +17.39% |
Insider Historical Profitability
| Finn Jonathan | director | 25000 0.0199% | $17,135.00 | 1 | 0 | |
| QUAY STEVEN C | President & CEO | 4826858 3.8369% | $3.31M | 3 | 1 | <0.0001% |
| Chen Shu-Chih | 4348315 3.4565% | $2.98M | 3 | 1 | <0.0001% | |
| CROSS ALEXANDER D | director | 88866 0.0706% | $60,908.76 | 1 | 0 | |
| Guse Kyle | CFO, Gen Counsel and Secretary | 10000 0.0079% | $6,854.00 | 1 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$4,786,289 | 136 | 5.55% | $90.47M | |
$49,091,668 | 110 | 13.11% | $78.19M | |
$155,580,641 | 77 | -24.21% | $83.64M | |
$47,282,828 | 47 | -17.38% | $90.39M | |
$329,102,560 | 42 | 30.96% | $77.11M |
ATOS Institutional Investors: Active Positions
| Increased Positions | 41 | +48.81% | 3M | +10.5% |
| Decreased Positions | 29 | -34.52% | 230,194 | -0.84% |
| New Positions | 12 | New | 159,629 | New |
| Sold Out Positions | 8 | Sold Out | 72,780 | Sold Out |
| Total Postitions | 96 | +14.29% | 30M | +9.65% |
ATOS Ownership Change vs Market
Institutional Investor Ownership
| Blackrock, Inc. | $7,476.00 | 7.75% | 9.76M | +91,934 | +0.95% | 2024-12-31 |
| Vanguard Group Inc | $5,070.00 | 5.25% | 6.62M | +20,673 | +0.31% | 2024-12-31 |
| Geode Capital Management, Llc | $2,156.00 | 2.23% | 2.81M | -269 | <0.01% | 2024-12-31 |
| State Street Corp | $1,345.00 | 1.39% | 1.76M | +23,148 | +1.34% | 2024-12-31 |
| Renaissance Technologies Llc | $1,193.00 | 1.24% | 1.56M | +247,562 | +18.9% | 2024-12-31 |
| Ubs Group Ag | $862.00 | 0.89% | 1.12M | +1M | +1,488.72% | 2024-12-31 |
| Northern Trust Corp | $786.00 | 0.81% | 1.03M | +71,525 | +7.5% | 2024-12-31 |
| Morgan Stanley | $346.00 | 0.36% | 452,196 | -5,324 | -1.16% | 2024-12-31 |
| Citadel Advisors Llc | $328.00 | 0.34% | 427,820 | +265,921 | +164.25% | 2024-12-31 |
| Jpmorgan Chase & Co | $277.00 | 0.29% | 361,296 | +211,654 | +141.44% | 2024-12-31 |